Guidance, NICE advice and quality standards in development | Guidance

Showing 351 to 360 of 450

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]	Technology appraisal guidance	TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]	Technology appraisal guidance	TBC
Rocatinlimab for treating moderate to severe atopic dermatitis in people 12 years and over [ID6565]	Technology appraisal guidance	TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]	Technology appraisal guidance	TBC
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]	Technology appraisal guidance	TBC
Ruxolitinib for Prurigo Nodularis [ID6571]	Technology appraisal guidance	TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]	Technology appraisal guidance	TBC
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]	Technology appraisal guidance	TBC
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer untreated with BCG ID6454	Technology appraisal guidance	TBC
School-based interventions: physical and mental health and wellbeing promotion	Quality standard	TBC